2025年12月，SKG母公司未来穿戴健康科技股份有限公司第三次向资本市场发起冲击，正式向港交所递交上市 申请，这场从A股创业板折戟、北交所辅导终止到转战港股的资本闯关，成为消费健康赛道的焦点。 | 纂]的[编纂]數目 | | : [编纂]股H股(視乎[编纂]行使與否 | | --- | --- | --- | | | | 而定) | | [编纂]數目 | .. | [编纂]股H股(可予[编纂]) | | [编纂]數目 | .. | [編纂]股H股(可予[編纂]及視乎[編纂]行使與 | | | | 否而定) | | 最高 编纂] | : | 每股H股[编纂]港元,另加1.0%經紀佣金、 | | | | 0.00015% 會財局交易徵費、0.0027%證監會 | | | | 交易徵費及0.00565%聯交所交易費(須於[编 | | | | 纂]時以港元繳足,多繳款項可予退還) | | 面值 | :: | 每股H股人民幣1.00元 | | 【编纂】 | : [·] | | 图源/SKG招股书 SKG由刘杰、徐思英夫妇创立，公司2007年成立之初深耕白色家电领域，2016年推出首款颈椎按摩仪完成战略 转型，精准卡位 ...

Core Viewpoint - The actual controller of Beiliangong, Ma Xuejun, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected market manipulation, marking the second investigation within a month [2][5]. Group 1: Company Background - Beiliangong was established in 2001 and went public on the Sci-Tech Innovation Board in July 2021, focusing on the design, research, development, production, sales, and service of smart portable health hardware, including products like neck and eye massagers [2]. - Ma Xuejun has been leading the company since its inception and currently holds a direct shareholding of 37.51%, controlling a total of 49.38% of the company's shares [2]. Group 2: Regulatory Issues - Ma Xuejun has previously faced regulatory inquiries due to fund occupation issues, including the misappropriation of 16.69 million yuan through employee loans and transferring 54 million yuan via related enterprises [3]. - In 2024 alone, the total amount of funds occupied reached 85.93 million yuan, with some amounts still unpaid by the end of the period [4]. Group 3: Financial Performance - Beiliangong reported a revenue of 1.085 billion yuan and a net profit of only 10.25 million yuan in its 2024 annual report, while the 2025 Q3 report indicated total assets of 676 million yuan and liabilities of 398 million yuan, leaving shareholders' equity at 278 million yuan [4]. - The company has faced continuous losses, with a projected net profit loss of 84 million to 105 million yuan for the entire year of 2025, and has received performance inquiry letters from the Shanghai Stock Exchange for four consecutive years, highlighting ongoing issues with information disclosure compliance [4].

Core Viewpoint - The company Beike (688793.SH) is under investigation by the China Securities Regulatory Commission (CSRC) for market manipulation, involving its actual controller and chairman, Ma Xuejun, who has been investigated twice in a short period for various financial misconducts [1][2]. Group 1: Company Background - Beike was established in 2001 and went public on the Sci-Tech Innovation Board in July 2021, focusing on the design, research, development, production, sales, and service of smart portable health hardware, including products like neck and eye massagers [1]. - Ma Xuejun has been the main operator since the company's inception, holding a direct stake of 37.51% and controlling a total of 49.38% of the shares, giving him absolute control over the company [1]. Group 2: Financial Misconduct - Ma Xuejun has been involved in various financial misconducts, including the misappropriation of company funds totaling 16.69 million yuan through employee loans, transferring 54 million yuan via related companies, and prepaying suppliers, with a total of 85.93 million yuan misappropriated in 2024 alone [2]. - The company has also failed to disclose 30 million yuan in illegal guarantees, raising further concerns about its governance [2]. Group 3: Financial Performance - In 2024, Beike reported revenues of 1.085 billion yuan and a net profit of only 10.25 million yuan. By the third quarter of 2025, the company's total assets were 676 million yuan, liabilities were 398 million yuan, and shareholders' equity was reduced to 278 million yuan, with a negative cash flow from operating activities of 28.1 million yuan [3]. - As of February 6, 2026, the company's stock price was 22.71 yuan per share, reflecting a decline of approximately 81.5% from its peak market value, with a total market capitalization of 1.952 billion yuan [3]. Group 4: Regulatory Response - The company stated that the investigation pertains to Ma Xuejun personally and is not expected to significantly impact its daily operations, with Ma continuing to fulfill his duties and the company pledging to cooperate with the regulatory investigation [3].

Core Viewpoint - Future Wearable Technology Co., Ltd. (referred to as "the company") is making its third attempt to go public, this time targeting the Hong Kong stock market after previous attempts on the Shenzhen and Beijing exchanges. The company aims to leverage its strong brand in health and wellness to secure capital investment [1][3]. Financial Performance - The company reported revenues of 9.04 billion yuan in 2022, projected to reach 10.45 billion yuan in 2024, with a return on equity of 18.4% [1][4]. - For the first three quarters of 2025, the company achieved revenues of 8.78 billion yuan, reflecting a year-on-year growth of 16.22%, and a net profit of 1.06 billion yuan, up 24.92% [4][8]. - The gross profit margin for the company was reported at 49.43% in 2022, with a slight increase to 49.72% in 2023 [5]. Market Position - According to a report by Frost & Sullivan, the company holds a 21.5% market share in China's smart wearable device market, ranking first among domestic companies, and a global market share of 4.1% [6]. - The company has filed for over 2007 patents and invested 42.02 million yuan in R&D in the first half of 2024, receiving multiple international design awards [6]. Challenges and Concerns - The company's core revenue-generating segment, smart wearable devices, saw only a 0.2% increase in revenue for the first three quarters of 2025, with a significant decline of 18.41% in its waist comfort products in 2024 [8][10]. - The company declared dividends of 1.99 billion yuan, exceeding its net profit of 1.06 billion yuan for the same period, resulting in a dividend payout ratio of 187.74%, raising concerns about its cash management [10][20]. - Marketing expenses for overseas expansion have significantly outpaced revenue growth, with overseas revenue at only 28.54 million yuan in the first half of 2024, while marketing costs reached 118 million yuan [14][20]. Strategic Initiatives - The company is focusing on international expansion as a key growth strategy, having previously faced challenges in entering overseas markets. It has signed a strategic investment cooperation agreement with Morgan Stanley to accelerate its global presence [10][20]. - The company is replicating its domestic marketing strategies on platforms like Amazon and Walmart, offering substantial discounts during promotional events [10][13].

Core Viewpoint - The company Beiqing Song, known as the "first stock of portable massagers," is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to a significant drop in its stock price and market value [1][5]. Financial Performance - In Q3 2025, the company's revenue was approximately 167 million yuan, a year-on-year decrease of 28.51%, with a net loss attributable to shareholders of about 29.51 million yuan. For the first three quarters, revenue was around 552 million yuan, down 34.07%, and the net loss was approximately 65.63 million yuan, a staggering increase of 600.98% in losses compared to the previous year [1]. Marketing and Operational Strategy - The company has been criticized for its "heavy marketing, light R&D" approach, with research and development expense ratios from 2021 to 2024 being 3.97%, 6.40%, 4.59%, and 5.38%, while sales expense ratios were significantly higher at 40.75%, 53.84%, 53.94%, and 50.16% [2]. Internal Governance Issues - Internal governance has been a concern, particularly regarding the actual controller Ma Xuejun's fund occupation issues. The company has reported instances of fund occupation through employee loans and prepayments to suppliers, totaling over 40.8 million yuan [4][5]. Shareholder Actions - On the day before the investigation announcement, Ma Xuejun sold approximately 2.55 million shares at 25.35 yuan per share, raising over 64 million yuan. This reduced his shareholding from 40.48% to 37.51%, and the combined shareholding with his associates fell below 50% [5][6]. Legal Challenges - The company is also facing a patent infringement lawsuit from Da Dong Electric Industrial Co., Ltd., which demands the cessation of manufacturing and sales of the disputed products, along with compensation of 10 million yuan. The company claims that the products involved are not core to its recent revenue [6].

Core Viewpoint - Future Health, the parent company of the popular massage device brand SKG, is attempting to enter the capital market through the Hong Kong Stock Exchange after two failed attempts to list on the A-share market. The company has shown steady profit growth over the past three years, with a gross margin of around 50%, significantly higher than typical home appliances. However, concerns arise from its heavy reliance on marketing over research and development, as well as its financial practices of high dividends alongside increasing debt [1][2]. Group 1: Company Performance and Financials - Future Health was established in November 2007 and has made multiple attempts to list on the A-share market, including a withdrawal of its application in August 2023. The company plans to list on the North Exchange after being delisted from the New Third Board in November 2023 [2]. - The company reported revenues of 904 million yuan, 1.046 billion yuan, and 1.045 billion yuan for the years 2022, 2023, and 2024 respectively, with net profits of 119 million yuan, 127 million yuan, and 135 million yuan for the same years. In the first nine months of 2025, it achieved revenue of 878 million yuan and a net profit of 106 million yuan [2]. - Future Health's gross margins for 2022, 2023, and 2024 were 50.4%, 49.1%, and 48.9% respectively, indicating strong profitability compared to other appliance categories [5]. Group 2: Marketing and R&D Strategy - The company has increasingly focused on marketing, with marketing expenses rising to 22.6% of total revenue by 2025, while R&D spending has decreased to 6.6% of revenue [1][7]. - Future Health's marketing strategy includes partnerships with celebrities and influencers, utilizing platforms like Douyin and Xiaohongshu to enhance user engagement and brand loyalty [6][8]. Group 3: Financial Practices and Governance - Prior to its IPO, Future Health distributed a total of 280 million yuan in dividends, which accounted for 74% of its net profit during that period. This included a significant dividend payout of 199.4 million yuan in the first nine months of 2025 [8]. - The company's debt increased from 94 million yuan at the end of 2022 to 204 million yuan by September 2025, raising concerns about its financial management practices, particularly the juxtaposition of high dividends and rising debt [8].

Core Viewpoint - The company Future Health is attempting to go public on the Hong Kong Stock Exchange after unsuccessful attempts to list on the A-share market, highlighting concerns over its marketing-heavy strategy and low R&D investment [1][2]. Group 1: Company Performance - Future Health has shown steady net profit growth over the past three years, with high gross margins around 50%, significantly exceeding typical household appliance margins [1][5]. - The company's revenue for 2022, 2023, and 2024 is reported at 904 million, 1.046 billion, and 1.045 billion respectively, with net profits of 119 million, 127 million, and 135 million [2]. - In the first nine months of 2025, the company achieved a revenue of 878 million and a net profit of 106 million [2]. Group 2: Marketing and R&D Strategy - Future Health's marketing expenses have increased, accounting for 22.6% of revenue, while R&D investment has decreased to 6.6% [1][7]. - The company relies heavily on online sales channels, which contributed 60.2% of its revenue in 2022, decreasing to 49.3% by 2025 [6]. - The company employs various marketing strategies, including celebrity endorsements and social media engagement, with marketing expenses rising from 1.64 billion in 2022 to 1.98 billion in the first nine months of 2025 [6][7]. Group 3: Financial Practices and Concerns - Future Health has distributed a total of 280 million in dividends prior to its IPO, raising concerns about its financial practices, especially as it simultaneously increased its debt from 94 million to 204 million [8]. - The company's ownership structure is heavily concentrated, with the founders controlling over 85% of the voting rights, leading to questions about governance and financial transparency [8]. Group 4: Industry Context - The wearable health device market in China is projected to grow from 30.9 billion in 2019 to 61.5 billion by 2024, with a compound annual growth rate of 15.9% expected from 2024 to 2029 [3]. - Future Health is positioned as a leader in the smart wearable health device sector, holding a 21.5% market share in 2024 [2]. - The competitive landscape is characterized by a focus on technology and market segmentation, with leading companies holding over 25% of the market share [4].

Core Viewpoint - The company Future Health, the parent of the massage device brand SKG, has submitted a listing application to the Hong Kong Stock Exchange, marking its third attempt to enter the capital market after previous setbacks [1][6]. Company Overview - Future Health was established in 2007 by founder Liu Jie, who transitioned from the restaurant and coal mining industries to focus on small home appliances before pivoting to wearable health products in 2016 with the launch of a cervical massager [3][5]. - The company has successfully positioned its products as essential for urban consumers, particularly in office settings, leveraging microcurrent technology to simulate manual massage [5]. Market Position and Product Strategy - SKG has maintained the largest market share in China's smart wearable relaxation device sector, with a projected market share of 21.5% in 2024 [5]. - The product line includes various massage devices and health monitoring tools, targeting both everyday wellness and professional rehabilitation [5]. - The company employs a three-pronged strategy of technology-driven innovation, experiential marketing, and targeted product development to capture niche markets [5]. Financial Performance - Revenue figures from 2022 to 2024 show slight growth, with revenues of 904 million RMB, 1.046 billion RMB, and 1.045 billion RMB respectively, while profits increased from 119 million RMB to 135 million RMB [10]. - In the first three quarters of 2025, the company reported a revenue of 878 million RMB, a year-on-year increase of 16.22%, with profits rising by 24.92% to 106 million RMB [10]. Challenges and Strategic Concerns - The company has faced significant challenges in its IPO journey, including compliance issues that led to the withdrawal of its application in 2023 and a failed attempt to list on the Beijing Stock Exchange [6]. - Recent financial maneuvers, including aggressive dividend payouts totaling 280 million RMB, have raised questions about the company's long-term intentions and financial health [16]. - The company has been criticized for its heavy marketing expenditures, which significantly outpace its research and development investments, raising concerns about its commitment to innovation [21]. Industry Context - The global market for smart wearable health devices is projected to grow from 41.7 billion USD in 2024 to 79.5 billion USD by 2029, with a compound annual growth rate of 13.8% [22]. - The Chinese market for smart wearable health devices is expected to reach 128.3 billion RMB by 2029, growing at a compound annual growth rate of 15.9% from 2024 [22]. - The competitive landscape in the smart relaxation device market is fragmented, with increasing competition leading to product homogenization, necessitating continuous innovation and effective marketing strategies [22].

Core Viewpoint - The first "Fuqing Table Tennis Tournament" in Fuan City aims to integrate sports, culture, and tourism, enhancing local economic development and city image [3][8]. Group 1: Event Overview - The tournament opened on October 1, 2023, at the Fuan Sports Center, featuring over a thousand attendees, including world champions [1][3]. - The event includes various competitions from October 1 to 3, showcasing local teams and promoting community engagement [3][5]. Group 2: Cultural Integration - The event features cultural performances, such as the She ethnic dance and local songs, highlighting Fuan's rich cultural heritage [3][5]. - A "Fuqing Theme Carnival" is organized alongside the tournament, offering local delicacies and cultural experiences to visitors [5][7]. Group 3: Economic Impact - Fuan City has been recognized as a "National Advanced County for Sports," with numerous sports associations and events contributing to community fitness [7]. - Official data indicates that from January to June 2023, Fuan's tourism revenue reached 5.792 billion, a year-on-year increase of 11.3%, with visitor numbers growing by 13.6% [8].

Core Viewpoint - Future Health, the parent company of SKG, has officially terminated its IPO plans on the Beijing Stock Exchange due to strategic development needs, following a series of challenges in its previous IPO attempts [2][4]. Group 1: Company Overview - Future Health was established in 2007 and has evolved into a high-tech enterprise providing smart wearable health products, with its main brand being SKG, focusing on products like neck and eye massagers, and health watches [2][3]. - As of September 2023, over 80% of the company's revenue comes from wearable health products, with neck and waist massagers being the most significant product lines [3]. Group 2: Financial Performance - Future Health's revenue from 2021 to 2024 was as follows: 1.054 billion, 904 million, 1.046 billion, and 1.048 billion yuan, while net profits were 131 million, 119 million, 127 million, and 135 million yuan respectively [3]. - The company has faced scrutiny regarding its high cash dividends, which were 155 million and 160 million yuan in 2020 and 2021, exceeding its net profits for those years [5]. Group 3: IPO Journey - Future Health's IPO journey has been tumultuous, with multiple attempts and rejections, including a failed application for the ChiNext board in 2022 and a subsequent withdrawal of its application in July 2023 [4][6]. - The company had initially aimed to raise 1.6 billion yuan but later reduced its target to 1.29 billion yuan [4]. Group 4: International Expansion - In recent years, Future Health has focused on expanding its international presence, particularly through its SKG brand, which has increased investments in cross-border e-commerce platforms [7]. - The company signed a strategic investment agreement with Morgan Stanley, securing a significant investment to accelerate its overseas expansion [7]. - Despite increased marketing expenditures, the company's overseas revenue saw a decline of 14.18% in the first half of 2024, amounting to approximately 28.54 million yuan [8].